Novel treatment options for refractory germ cell tumors

G. Varuni Kondagunta; Guru Sonpavde; Matthew D. Galsky; Mark T. Fleming; Thomas E. Hutson; Cora N. Sternberg

doi:10.1016/j.uct.2008.10.001

Novel treatment options for refractory germ cell tumors

G. Varuni Kondagunta, Guru Sonpavde, Matthew D. Galsky, Mark T. Fleming, Thomas E. Hutson, Cora N. Sternberg

Research output: Contribution to journal › Review article › peer-review

Abstract

Although testicular germ cell tumors (GCTs) are a model for a curable neoplasm, a significant proportion will relapse and require salvage therapy. While currently available conventional and high-dose chemotherapy salvage regimens attain durable complete remissions in a significant proportion of patients, the long-term outcomes are still suboptimal in this young population. Several novel agents are being evaluated for recurrent germ cell tumors, including chemotherapeutic and biologic agents, notably anti-angiogenic agents. A better understanding of biology may lead to enhanced outcomes for cisplatin-refractory patients with germ cell tumors.

Original language	English
Pages (from-to)	89-96
Number of pages	8
Journal	Update on Cancer Therapeutics
Volume	3
Issue number	2
DOIs	https://doi.org/10.1016/j.uct.2008.10.001
State	Published - Dec 2008
Externally published	Yes

Keywords

Germ cell tumors
Novel agents
Salvage therapy

Access to Document

10.1016/j.uct.2008.10.001

Cite this

@article{addebfd8ab914801a793a6ff9effc086,

title = "Novel treatment options for refractory germ cell tumors",

abstract = "Although testicular germ cell tumors (GCTs) are a model for a curable neoplasm, a significant proportion will relapse and require salvage therapy. While currently available conventional and high-dose chemotherapy salvage regimens attain durable complete remissions in a significant proportion of patients, the long-term outcomes are still suboptimal in this young population. Several novel agents are being evaluated for recurrent germ cell tumors, including chemotherapeutic and biologic agents, notably anti-angiogenic agents. A better understanding of biology may lead to enhanced outcomes for cisplatin-refractory patients with germ cell tumors.",

keywords = "Germ cell tumors, Novel agents, Salvage therapy",

author = "Kondagunta, {G. Varuni} and Guru Sonpavde and Galsky, {Matthew D.} and Fleming, {Mark T.} and Hutson, {Thomas E.} and Sternberg, {Cora N.}",

year = "2008",

month = dec,

doi = "10.1016/j.uct.2008.10.001",

language = "English",

volume = "3",

pages = "89--96",

journal = "Update on Cancer Therapeutics",

issn = "1872-115X",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - Novel treatment options for refractory germ cell tumors

AU - Kondagunta, G. Varuni

AU - Sonpavde, Guru

AU - Galsky, Matthew D.

AU - Fleming, Mark T.

AU - Hutson, Thomas E.

AU - Sternberg, Cora N.

PY - 2008/12

Y1 - 2008/12

N2 - Although testicular germ cell tumors (GCTs) are a model for a curable neoplasm, a significant proportion will relapse and require salvage therapy. While currently available conventional and high-dose chemotherapy salvage regimens attain durable complete remissions in a significant proportion of patients, the long-term outcomes are still suboptimal in this young population. Several novel agents are being evaluated for recurrent germ cell tumors, including chemotherapeutic and biologic agents, notably anti-angiogenic agents. A better understanding of biology may lead to enhanced outcomes for cisplatin-refractory patients with germ cell tumors.

AB - Although testicular germ cell tumors (GCTs) are a model for a curable neoplasm, a significant proportion will relapse and require salvage therapy. While currently available conventional and high-dose chemotherapy salvage regimens attain durable complete remissions in a significant proportion of patients, the long-term outcomes are still suboptimal in this young population. Several novel agents are being evaluated for recurrent germ cell tumors, including chemotherapeutic and biologic agents, notably anti-angiogenic agents. A better understanding of biology may lead to enhanced outcomes for cisplatin-refractory patients with germ cell tumors.

KW - Germ cell tumors

KW - Novel agents

KW - Salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=57449110126&partnerID=8YFLogxK

U2 - 10.1016/j.uct.2008.10.001

DO - 10.1016/j.uct.2008.10.001

M3 - Review article

AN - SCOPUS:57449110126

SN - 1872-115X

VL - 3

SP - 89

EP - 96

JO - Update on Cancer Therapeutics

JF - Update on Cancer Therapeutics

IS - 2

ER -

Novel treatment options for refractory germ cell tumors

Abstract

Keywords

Access to Document

Fingerprint

Cite this